ENHANCING VACCINAL PREVENTION OF THE HUMAN PAPILLOMA VIRAL (HPV) INFECTION: PROTECTING PEOPLE OF DIFFERENT AGE AND SEX FROM A RANGE OF HPV-ASSOCIATED DISEASES

Abstract

HPV is the most widespread sexually transmitted infection. HPV affects men and women regardless of age and leads to the development of various anogenital area diseases. International studies proved a wide clinical range of the tetravalent HPV vaccine protection and allowed recommending it for the prevention of not only cervical cancer, but also of vulvar, vaginal and anal cancer and anogenital condylomae in patients of both sexes. 42 countries have already introduced national HPV-vaccination programs in compliance with WHO recommendations. Anogenital area cancer morbidity reduction in these countries is expected in 10-15 years. However, a reduction or even complete disappearance of anogenital condylomae among the population has already been noted in a range of countries because the incubation period of this disease is short; this is the first marker of vaccination efficacy in a population.

Keywords

• human papilloma virus
• cervical cancer
• senior women
• genital condylomae
• hpv types
• sexual activity
• vaccinal prevention
• tetravalent vaccine